"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
There has been little detailed investigation of the metabolic fate of Ethiodol (ethiodized oil) in either man or animals. However, the fate of Ethiodol (ethiodized oil) following Lymphangiography in dogs has been reported.1 Koehler et al. employed I131–tagged Ethiodol (ethiodized oil) for lymphangiography in dogs and analyses of individual organs at various time intervals were done. The investigators reported an average of only 25% of the injected medium was retained in the lymphatics at the end of three days. An average of 50% was recovered from the lungs. They found the remainder of injected activity was fairly uniformly distributed throughout the body. Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.
1. P. Ruben Koehler, M.D. et al.:“Body Distribution of Ethiodol (ethiodized oil) Following Lymphangiography”, Radiology, 1964, 82, 5 866-871.
Last reviewed on RxList: 6/4/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Ethiodol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.